The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

Dr Syed Faraz Ahmed

+61383444000 | faraz.ahmed@unimelb.edu.au

Position:
Research Fellow
Theme(s):
Antimicrobial Resistance
Discipline(s):
Discovery Research, Computational Science and Genomics
Unit(s):
The University of Melbourne, Department of Microbiology and Immunology (DMI)
Lab Group(s):
Matthew McKay Group

Dr. Ahmed is an early career researcher with joint appointment at Department of Electrical and Electronic Engineering and Department of Microbiology and Immunology.

Dr Ahmed's current research interests involve developing innovative ways to inform design of next generation vaccines and antiviral drugs against infectious diseases. My research adopts a data science perspective aiming to identify fragments of viral proteins and genes that could be effectively targeted through vaccines or drugs. Overall, addressing a fundamental question in developing effective vaccines and drugs by closely collaborating with experimental researchers and translating the results into practical impact.

  • Key Achievements
    • Dr Ahemd has authored 17 papers, including seven as first author, with two publications as cover articles in Viruses journal and as well as a highly cited first-author paper.

      His COVID-19 research influenced vaccine development and design of commercial T cell immunoassays. His research has been recognised globally as a Young Scientist of the Hong Kong Laureate Forum in 2023. He aims to lead research on design of programmable RNA drugs and next-generation vaccines for infectious viruses.

    Publications
    Loading ORCID data…
    Research Groups
    • Matthew McKay Group

      The McKay Group focuses on developing computational models, statistical and machine learning methods to address problems in infectious diseases and immunology. Current research is aimed at understanding virus evolution and immune escape and for identifying potent targets for next-generation vaccines.